Aripiprazole Once-monthly in Patients With Schizophrenia

Patients will be recruited among those who complete treatment with aripiprazole in Study
14724A / NCT01795547.

Inclusion Criteria:

- The patient is judged to potentially benefit from 24-week treatment with aripiprazole
once-monthly according to the clinical opinion of the investigator.

- The patient agrees to protocol-defined use of effective contraception.

Exclusion Criteria:

- The patient has been diagnosed with a primary psychiatric disorder other than
schizophrenia during Study 14724A / NCT01795547.

- The patient has a clinically significant unstable illness diagnosed during Study
14724A / NCT01795547.

- The patient is at significant risk of harming himself/herself or others according to
the investigator's judgement or according to Columbia-Suicide Severity Rating Scale
(C-SSRS).

- The patient has a disease or takes medication that could, in the investigator's
opinion, interfere with the assessments of safety, tolerability or efficacy, or
interfere with the conduct or interpretation of the study.

- The patient has one or more clinical laboratory test values outside the reference
range, based on the blood or urine samples taken during the conduct of Study 14724A /
NCT01795547 that are, in the investigator's opinion, of potential risk to the
patient's safety.

- The patient is, in the investigator's opinion, unlikely to comply with the protocol
or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.